Who
Clare Kahn
Director
Company insider
Files Form 4 as: Director, Solid Biosciences; Director, Stoke Therapeutics.
In numbers
- Trades disclosed
- 13
- Buys
- 2
- Sells
- 0
- Bought
- $18K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 2 Mar 2021
- Last trade
- 10 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 11 Jun 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 3 Apr 2026filed 7 Apr 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,782 at $0.00 | filing |
| 3 Apr 2026filed 7 Apr 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,782 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 11 Mar 2025filed 13 Mar 2025 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Bought | $9,9321,860 at $5.34 | filing |
| 11 Jun 2024filed 13 Jun 2024 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,400 at $0.00 | filing |
| 7 Jun 2024filed 11 Jun 2024 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Bought | $8,4371,100 at $7.67 | filing |
| 6 Jun 2023filed 8 Jun 2023 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,650 at $0.00 | filing |
| 13 Dec 2022filed 15 Dec 2022 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,650 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Mar 2021filed 4 Mar 2021 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Solid Biosciences (NASDAQ:SLDB) Upgraded at UBS GroupSLDB · tickerreport.com · 17 Oct 2026Solid Biosciences (NASDAQ:SLDB) Stock Lifted to Strong-Buy by UBS GroupSLDB · tickerreport.com · 17 Oct 2026Solid Biosciences Inc. (NASDAQ:SLDB) Stock Has Average Price Target of $18.69SLDB · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Clare Kahn; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.